2023
Donor Hemoglobin Genotype Does Not Impact Outcomes Following Matched Related Donor Hematopoietic Cell Transplantation for Sickle Cell Disease: A STAR Study
Stenger E, John T, Chellapandian D, Shah R, Gillespie S, Xiang Y, Liu K, Bhatia M, Guilcher G, Jaroscak J, Kasow K, Krajewski J, Ngwube A, Rangarajan H, Horan J, Krishnamurti L, Shenoy S, Abraham A. Donor Hemoglobin Genotype Does Not Impact Outcomes Following Matched Related Donor Hematopoietic Cell Transplantation for Sickle Cell Disease: A STAR Study. Blood 2023, 142: 4955. DOI: 10.1182/blood-2023-188514.Peer-Reviewed Original ResearchHematopoietic cell transplantationSickle cell diseaseDonor hematopoietic cell transplantationLong-term outcomesPost-HCTOrgan dysfunctionCell transplantationCell diseaseRelated donor hematopoietic cell transplantationSignificant differencesVaso-occlusive pain crisesComparable long-term outcomesLong-term outcome dataLast platelet transfusionMarkers of hemolysisCategorical variablesSymptom-free survivalSignificant organ dysfunctionHb AASickle cell traitContinuous variablesSevere clinical phenotypeSevere disease phenotypeChronic GVHDPain crisis
2021
13 Resolution of Serious Vaso-Occlusive Pain Crises: Results from the Ongoing Phase 1/2 HGB-206 Group C Study of LentiGlobin for Sickle Cell Disease (SCD; bb1111) Gene Therapy
Walters M, Thompson A, Mapara M, Kwiatkowski J, Krishnamurti L, Aygun B, Kasow K, Rifkin-Zenenberg S, Schmidt M, DelCarpini J, Pierciey F, Miller A, Chen R, Goyal S, Kanter J, Tisdale J. 13 Resolution of Serious Vaso-Occlusive Pain Crises: Results from the Ongoing Phase 1/2 HGB-206 Group C Study of LentiGlobin for Sickle Cell Disease (SCD; bb1111) Gene Therapy. Transplantation And Cellular Therapy 2021, 27: s12-s13. DOI: 10.1016/s2666-6367(21)00039-7.Peer-Reviewed Original Research
2015
A multicenter randomized controlled trial of intravenous magnesium for sickle cell pain crisis in children
Brousseau D, Scott J, Badaki-Makun O, Darbari D, Chumpitazi C, Airewele G, Ellison A, Smith-Whitley K, Mahajan P, Sarnaik S, Casper T, Cook L, Dean J, Leonard J, Hulbert M, Powell E, Liem R, Hickey R, Krishnamurti L, Hillery C, Nimmer M, Panepinto J, Network F. A multicenter randomized controlled trial of intravenous magnesium for sickle cell pain crisis in children. Blood 2015, 126: 1651-1657. PMID: 26232172, PMCID: PMC4591790, DOI: 10.1182/blood-2015-05-647107.Peer-Reviewed Original ResearchConceptsSickle cell pain crisisLength of stayPediatric Emergency Care Applied Research NetworkPain crisisIntravenous magnesiumOpioid useNormal saline placeboStudy drug infusionPlacebo-controlled trialHealth-related qualityQuality of lifeMorphine equivalentsStudy drugSaline placeboSecondary outcomesStandard therapyHemoglobin SSPediatric patientsPrimary outcomeDrug infusionPain relieversPlaceboStayChildren 4Group demographics
2014
A Multi-Center Randomized Controlled Trial of Intravenous Magnesium for Sickle Cell Pain Crisis in Children
Brousseau D, Scott J, Badaki O, Darbari D, Chumpitazi C, Airewele G, Ellison A, Smith-Whitley K, Mahajan P, Sarnaik S, Casper T, Cook L, Dean M, Leonard J, Hulbert M, Powell E, Liem R, Hickey R, Krishnamurti L, Hillery C, Panepinto J. A Multi-Center Randomized Controlled Trial of Intravenous Magnesium for Sickle Cell Pain Crisis in Children. Blood 2014, 124: 88. DOI: 10.1182/blood.v124.21.88.88.Peer-Reviewed Original ResearchSickle cell pain crisisLength of stayAcute chest syndromePediatric Emergency Care Applied Research NetworkQuality of lifePain crisisPediatric emergency medicine physiciansOpioid useIntravenous magnesiumSickle cell diseaseEmergency medicine physiciansMorphine equivalentsPlacebo groupStudy drugAdverse eventsDrug infusionCell diseaseMedicine physiciansHistory of ACSMAGIC studyMulti-Center Randomized Controlled TrialSickle cell vasoocclusive crisisAcute intervention trialDecreased opioid useFirst drug infusionDoes e-pain plan improve management of sickle cell disease associated vaso-occlusive pain crisis? A mixed methods evaluation
Kato-Lin Y, Krishnamurti L, Padman R, Seltman H. Does e-pain plan improve management of sickle cell disease associated vaso-occlusive pain crisis? A mixed methods evaluation. International Journal Of Medical Informatics 2014, 83: 814-824. PMID: 25179666, DOI: 10.1016/j.ijmedinf.2014.08.003.Peer-Reviewed Original ResearchConceptsVaso-occlusive pain crisesSickle cell diseasePain managementMixed-methods evaluationPain crisisEmergency departmentHealth information technologyCell diseaseInpatient unitSickle cell disease patientsIndividualized pain plansAnalgesic ordersPain planED visitsFirst dosePediatric patientsChildren's HospitalDisease patientsHigh baseline performanceClinicians insightNurses' perspectivesPatient recordsHealth information systemsSimple interventionCare quality
2012
Mobile Directly Observed Therapy: Monitoring and Improving Hydroxyurea Adherence in Pediatric Sickle Cell Patients
Creary S, Gladwin M, Krishnamurti L. Mobile Directly Observed Therapy: Monitoring and Improving Hydroxyurea Adherence in Pediatric Sickle Cell Patients. Blood 2012, 120: 2060. DOI: 10.1182/blood.v120.21.2060.2060.Peer-Reviewed Original ResearchSickle cell diseaseMedication possession ratioPediatric sickle cell diseaseLaboratory markersPediatric sickle cell patientsMorisky Medication Adherence ScaleAcute chest syndromeFrequent pain crisesHemoglobin F percentageHemoglobin SS diseasePrescription refill recordsMedication Adherence ScaleAnti-tuberculosis therapyPoor medication adherenceLarge clinical trialsRed blood cell disordersSelf-reported adherenceSickle cell patientsBlood cell disordersDOT participantsHU adherenceChest syndromePain crisisMedication ingestionPossession ratio
2011
Clinical trial implementation and recruitment: Lessons learned from the early closure of a randomized clinical trial
Peters-Lawrence M, Bell M, Hsu L, Osunkwo I, Seaman P, Blackwood M, Guillaume E, Bellevue R, Krishnamurti L, Smith W, Dampier C, Minniti C, Network F. Clinical trial implementation and recruitment: Lessons learned from the early closure of a randomized clinical trial. Contemporary Clinical Trials 2011, 33: 291-297. PMID: 22155024, PMCID: PMC3577351, DOI: 10.1016/j.cct.2011.11.018.Peer-Reviewed Original ResearchConceptsNew England Research InstituteClinical trialsRandomized clinical trialsFuture clinical trialsClinical trial implementationComplex dosing schedulesClinical Research NetworkPatient Controlled AnalgesiaProtocol acceptanceSCD clinicPain controlPain crisisAcute painDosing schedulesAcute interventionOutside physiciansUrgent careEligibility criteriaEnrollment periodPatient encountersEarly closurePainRecruitment barriersTrialsStaff availabilityAssociation of Genetic Variation in the Catechol-O-Methyl Transferase Gene with Pain and Six Minute Walk Distance in Sickle Cell Anemia Patients From the Walk-PHaSST Study
Zhang Y, Zeng Q, Belfer I, Goel R, Porter M, Chu Y, Barst R, Hassell K, Machado R, Goldsmith J, Gladwin M, Krishnamurti L. Association of Genetic Variation in the Catechol-O-Methyl Transferase Gene with Pain and Six Minute Walk Distance in Sickle Cell Anemia Patients From the Walk-PHaSST Study. Blood 2011, 118: 1075. DOI: 10.1182/blood.v118.21.1075.1075.Peer-Reviewed Original ResearchSickle cell diseaseAcute pain crisisChronic painPain crisisPain phenotypesPain rateSCD painSevere painPain sensitivitySingle nucleotide polymorphismsAG genotype carriersChronic pain ratesSickle cell anemia patientsType of painAfrican American patientsGenetic factorsDescription of painLogistic regression analysisLower pain sensitivityCOMT genetic variantsChi-square testMultinomial logistic regression analysisCatechol-O-methyl transferase (COMT) genePain episodesMild painNitric Oxide for Inhalation in the Acute Treatment of Sickle Cell Pain Crisis: A Randomized Controlled Trial
Gladwin M, Kato G, Weiner D, Onyekwere O, Dampier C, Hsu L, Hagar R, Howard T, Nuss R, Okam M, Tremonti C, Berman B, Villella A, Krishnamurti L, Lanzkron S, Castro O, Gordeuk V, Coles W, Peters-Lawrence M, Nichols J, Hall M, Hildesheim M, Blackwelder W, Baldassarre J, Casella J, Investigators F. Nitric Oxide for Inhalation in the Acute Treatment of Sickle Cell Pain Crisis: A Randomized Controlled Trial. JAMA 2011, 305: 893-902. PMID: 21364138, PMCID: PMC3403835, DOI: 10.1001/jama.2011.235.Peer-Reviewed Original ResearchConceptsVaso-occlusive pain crisesSickle cell diseaseVisual analog pain scale scoreAcute chest syndromePrimary end pointPain scale scoresNitric oxideChest syndromePain crisisPainful crisesScale scoreSickle cell pain crisisSmall placebo-controlled trialsPlacebo-controlled clinical trialEnd pointNitric oxide gasCumulative opioid usageParenteral opioid useWhole blood nitritePlacebo-controlled trialSerious adverse eventsLength of hospitalizationSecondary outcome measuresEvidence of efficacyOpioid usage
2010
Chronic Pain Is An Independent Predictor of Lower 6 Minute Walk Distance In Patients with Sickle Cell Disease: Results From Walk-PHaSST Study
Krishnamurti L, Goel R, Castro O, Barst R, Rosenzweig E, Sachdev V, Machado R, Gibbs S, Little J, Schraufnagel D, Girgis R, Morris C, Badesch D, Lanzkron S, Goldsmith J, Gordeuk V, Kato G, Gladwin M, Hassell K. Chronic Pain Is An Independent Predictor of Lower 6 Minute Walk Distance In Patients with Sickle Cell Disease: Results From Walk-PHaSST Study. Blood 2010, 116: 2658. DOI: 10.1182/blood.v116.21.2658.2658.Peer-Reviewed Original ResearchTricuspid regurgitant velocityAcute pain crisisSickle cell diseasePain crisisChronic painExercise capacityIndependent predictorsClinical trialsCell diseaseAcute sickle cell pain crisisSickle cell pain crisisMultivariable logistic regression analysisSickle cellsAcute pain ratingsHypertension clinical trialsTrials of sildenafilDouble-blind placeboEmergency department visitsGroup of patientsMinute walk distanceWeeks of treatmentNon-drug therapyFuture clinical trialsSignificant lower odds ratioLogistic regression analysis
2009
National Burden of Emergency Department Care for Sickle Disease: Impact of Age, Insurance Status, Income, Hospital Type and Location On Subsequent Hospital Admission.
Goel R, Viswanathan P, Krishnamurti L. National Burden of Emergency Department Care for Sickle Disease: Impact of Age, Insurance Status, Income, Hospital Type and Location On Subsequent Hospital Admission. Blood 2009, 114: 2488. DOI: 10.1182/blood.v114.22.2488.2488.Peer-Reviewed Original ResearchNationwide Emergency Department SampleSickle cell diseaseEmergency department careED visitsNational burdenInsurance statusHospital typeICD-9-CM diagnosis codesState Emergency Department DatabasesPayer ED databaseSubsequent hospital admissionUncomplicated pain crisisED visit dataProportion of patientsEmergency Department SampleEmergency Department DatabasesHospital-based EDsState Inpatient DatabasesHigh-quality careImpact of agePain crisisSubsequent hospitalizationSuch potential factorDiagnosis patientsPatient age